Oragenics, Inc. (OGEN), on Tuesday announced a strategic partnership with BRAINBox Solutions to develop the first intranasal therapy for mild traumatic brain injury or mTBI, also known as concussion.
The collaboration aims to create a comprehensive "trigger-to-treat" platform, combining BRAINBox's advanced diagnostic technology with Oragenics' intranasal therapeutic candidate, ONP-002.
BRAINBox's proprietary diagnostic system uses neurological biomarkers, neuropsychological assessments, and AI-driven analytics to provide rapid and accurate concussion diagnoses.
Oragenics' ONP-002, a neurosteroid therapeutic, has shown promise in preclinical studies to mitigate brain injury effects and support recovery.
The goal is to offer a solution that addresses both the identification and treatment of mTBI, improving patient outcomes.
BRAINBox's diagnostic tools will play a critical role in Oragenics' upcoming Phase IIa clinical trials, allowing for precise patient selection and real-time monitoring of therapeutic efficacy.
This partnership represents a major step forward in concussion care, providing the potential for faster intervention and better long-term recovery for concussion patients.
Currently, OGEN is trading at $0.28 down by 0.52%.
For comments and feedback: editorial@rttnews.com